(vianews) - eurofins scient. (erf.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| eurofins scient. (erf.pa) | €56.30 | 1.83% | 9.12% |
| ucb (ucb.br) | €82.12 | 1.61% | 3.7% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. eurofins scient. (erf.pa)
1.83% forward dividend yield and 9.12% return on equity
eurofins scientific se, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. the company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. it provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. in addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, gmo, grain, meat, nano material, pesticides, and residual dna testing. further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. additionally, the company provides forensic, genomic, maritime, materials and engineering, reach, and technologies services. the company was founded in 1987 and is headquartered in luxembourg city, luxembourg.
earnings per share
as for profitability, eurofins scient. has a trailing twelve months eps of €2.28.
pe ratio
eurofins scient. has a trailing twelve months price to earnings ratio of 24.69. meaning, the purchaser of the share is investing €24.69 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.12%.
volatility
eurofins scient.'s last week, last month's, and last quarter's current intraday variation average was a negative 0.70%, a negative 0.31%, and a positive 1.20%.
eurofins scient.'s highest amplitude of average volatility was 0.70% (last week), 1.04% (last month), and 1.20% (last quarter).
dividend yield
as claimed by morningstar, inc., the next dividend payment is on jul 4, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1.83%.
moving average
eurofins scient.'s worth is below its 50-day moving average of €57.86 and below its 200-day moving average of €62.10.yearly top and bottom value
eurofins scient.'s stock is valued at €56.30 at 07:30 est, way under its 52-week high of €72.64 and above its 52-week low of €53.46.
more news about eurofins scient..
2. ucb (ucb.br)
1.61% forward dividend yield and 3.7% return on equity
ucb sa, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. the company's primary products include cimzia for inflammatory tnf mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; vimpat, keppra, and briviact for epilepsy; neupro for parkinson's disease and restless legs syndrome; nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and zyrtec and xyzal for allergies. it also offers evenity for the treatment of osteoporosis in postmenopausal women; bimzelx for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. in addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; bepranemab to treat alzheimer's disease; and ucb0599 to treat parkinson's disease. further, it engages in contract manufacturing activities. ucb sa has collaboration agreements with amgen, biogen, roche/genentech, novartis, otsuka, and doc.ai. it operates in the united states, japan, germany, rest of europe, spain, france, china, italy, the united kingdom, ireland, belgium, and internationally. the company was incorporated in 1925 and is headquartered in brussels, belgium.
earnings per share
as for profitability, ucb has a trailing twelve months eps of €1.7.
pe ratio
ucb has a trailing twelve months price to earnings ratio of 48.31. meaning, the purchaser of the share is investing €48.31 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.7%.
volatility
ucb's last week, last month's, and last quarter's current intraday variation average was 0.61%, 0.03%, and 0.85%.
ucb's highest amplitude of average volatility was 0.87% (last week), 0.74% (last month), and 0.85% (last quarter).
more news about ucb.